Polihidramnion

01Pathophysiology

Amniotic fluid volume is maintained by a dynamic balance between fetal urine production (the primary source of amniotic fluid in the second and third trimesters) and fetal swallowing (the primary route of fluid reabsorption). Polyhydramnios develops when this equilibrium shifts toward net fluid accumulation.

In maternal diabetes mellitus, fetal hyperglycemia leads to osmotic diuresis in the fetal kidneys, resulting in increased fetal urine output. This is the single most common identifiable cause and directly explains why poorly controlled diabetic mothers present with excessive amniotic fluid.

In fetal gastrointestinal obstruction (esophageal atresia, duodenal atresia, or any proximal bowel obstruction), the fetus physically cannot swallow amniotic fluid. The higher the level of obstruction, the more severe the polyhydramnios. This is why esophageal atresia produces more pronounced polyhydramnios than jejunal atresia. Notably, distal bowel obstructions (ileal or colonic atresia) typically do not cause polyhydramnios because the majority of fluid absorption occurs in the proximal small bowel.

In anencephaly and open neural tube defects, polyhydramnios results from two mechanisms: impaired fetal swallowing due to absent or dysfunctional brainstem swallowing centers, and transudation of fluid across exposed meninges and neural tissue.

In fetal hydrops (immune or nonimmune), high-output cardiac failure and increased capillary permeability lead to generalized fluid shifts. The fetus becomes edematous and produces excess urine secondary to elevated central venous pressure.

Importantly, in approximately 60-70% of cases, no identifiable cause is found, and the polyhydramnios is classified as idiopathic. These cases tend to be mild and carry a better prognosis than those with an identified etiology.

02Classification and Clinical Manifestation

Onset

03Diagnostic Workup

The best initial test is always an obstetric ultrasound measuring the amniotic fluid index. An AFI above 24 cm or a single deepest pocket above 8 cm confirms the diagnosis. Once polyhydramnios is established, the next step is a detailed fetal anatomic survey on the same ultrasound to look for structural anomalies. Pay close attention to the fetal stomach: an absent gastric bubble suggests esophageal atresia (the fetus is not swallowing), while a "double bubble" sign points to duodenal atresia.

Simultaneously, the maternal workup should include a glucose screen to rule out gestational or preexisting diabetes, an indirect Coombs test to evaluate for Rh alloimmunization, and TORCH serologies when infection is suspected.

If the anatomic survey reveals structural anomalies or if no cause is identified despite a thorough workup, amniocentesis for fetal karyotyping should be considered. This is particularly important because Trisomy 21 is associated with duodenal atresia, and Trisomy 18 carries multiple anomalies that can produce polyhydramnios.

Middle cerebral artery (MCA) Doppler is the noninvasive screening tool for fetal anemia. An elevated peak systolic velocity (> 1.5 MoM) indicates significant fetal anemia and should prompt consideration of cordocentesis or intrauterine transfusion.

04Management and Treatment

For mild idiopathic polyhydramnios, the standard approach is expectant management with serial ultrasound monitoring every 2-3 weeks and antenatal fetal surveillance using nonstress testing. Most mild cases resolve or remain stable and do not require intervention.

When polyhydramnios is moderate to severe and causing maternal respiratory compromise, the immediate intervention is therapeutic amnioreduction. This procedure involves inserting an 18-gauge spinal needle into the amniotic cavity under continuous ultrasound guidance and draining fluid slowly (no faster than 1 liter over 20 minutes) to reduce intrauterine pressure. The goal is symptomatic relief, not normalization of AFI. This procedure carries risks of preterm labor, placental abruption, and infection, so it should be reserved for symptomatic patients.

Indomethacin is the pharmacologic option for refractory polyhydramnios. It works by inhibiting prostaglandin synthesis, which decreases fetal renal blood flow and therefore reduces fetal urine production. The typical dose is 25 mg orally every 6 hours. However, indomethacin must not be used beyond 32 weeks of gestation because it causes premature closure of the ductus arteriosus. During treatment, serial fetal echocardiography must be performed every 48-72 hours to monitor for ductal constriction. If ductal narrowing is detected, the drug must be discontinued immediately.

When a treatable underlying cause is identified, management targets that cause directly. For maternal diabetes, tight glycemic control with insulin is the cornerstone. For Rh alloimmunization with fetal anemia, intrauterine transfusion addresses the root cause.

At the time of delivery, a controlled amniotomy is performed: the membranes are punctured with a needle rather than ruptured widely, allowing fluid to drain slowly. Rapid decompression risks umbilical cord prolapse (as the rushing fluid can sweep the cord past the presenting part) and placental abruption (from sudden reduction in uterine volume).

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on polyhydramnios questions is by failing to connect the fetal anomaly to the fluid abnormality. When a vignette describes a newborn with a blind-ending esophageal pouch or a "double bubble" on prenatal ultrasound, the question may ask what amniotic fluid finding was present during pregnancy. Students who do not understand that impaired fetal swallowing leads to polyhydramnios will miss these questions.

A second frequent trap involves indomethacin use after 32 weeks. A vignette may describe a 34-week pregnancy with worsening polyhydramnios and offer indomethacin as an answer choice. This is wrong because of the risk of premature ductal closure, and the correct answer would be amnioreduction.

Another tested concept is the distinction between proximal and distal GI obstruction. Polyhydramnios pairs with proximal obstruction (esophageal atresia, duodenal atresia). A vignette describing a distal obstruction (such as Hirschsprung disease or imperforate anus) with polyhydramnios should raise doubt about whether that is truly the diagnosis being described.

Finally, remember that the delivery management pearl is controlled amniotomy. A question describing a woman with polyhydramnios in labor may ask about the risk of rapid membrane rupture. The tested concept here is understanding that rapid fluid release causes cord prolapse and placental abruption, and that slow, controlled drainage is the correct approach.

The core competency tested across all polyhydramnios questions is the ability to reason backward from a fluid volume abnormality to its underlying cause, and to sequence both the diagnostic workup and the management in the correct clinical order.